Introduction
The impact of aggressive glucose control in hospitals, and the critical care setting in particular, continues to be an area of intense study. While the general clinical consensus regards hyperglycemia as a dangerous condition that should be carefully managed, ongoing research has produced variable results related to disparate patient populations, blood glucose (BG) targets, and insulin treatment strategies. [1] [2] [3] [4] [5] [6] [7] Consequently, expert opinions regarding optimal target range and management strategies have not been definitive. 8, 9 Additionally, questions have been raised about the safety of intensive insulin therapy due to the potential harm of iatrogenic hypoglycemia. [10] [11] [12] Regardless of this ongoing inquiry, many hospitals have implemented or are moving toward establishing glycemic control programs in an effort to manage inpatient hyperglycemia, particularly in the critically ill. 13, 14 These programs are most successful with multidisciplinary involvement; extensive, coordinated, multipronged clinician education; and measurement through quality improvement approaches. 15, 16 While some programs have been in place for several years now, reports on the current state of glycemic control in hospitals have demonstrated that considerable opportunity exists for improvement. 17, 18 A critical finding from surveys directed at determining current glycemic control practices indicates that most hospitals are, in fact, unable to determine their current glucose metrics [17] [18] [19] and to measure the impact of their glycemic control programs because the hospitals do not have access to data to track the current state and improvement. 20, 21 The Remote Automated Laboratory System (RALS) Report software [Medical Automation Systems (MAS), Charlottesville, VA] was designed to meet this need. 17 The RALS Report enables participants to review their facilities' glucose metrics compared to a national benchmark of data gathered from 576 U.S. hospitals. This benchmarking initiative utilizes BG measures captured by point-of-care (POC) glucose meters to provide high-level analyses of the state of glycemic control in hospitalized patients.
Methods
The hospitals in this analysis employed standard bedside glucose meters (ACCU-CHEK ® Inform, Roche Diagnostics, Indianapolis, IN) downloaded to the RALS-Plus (MAS, Charlottesville, VA) a well-established POC test information management system. 22 A proprietary software application was added to the existing RALS-Plus data management system in each hospital site, with subscription to the benchmarking reports. This application automatically extracts de-identified patient BG levels, which are then transferred via a secured internet connection to MAS, where reports are created and sent to the subscribers electronically. (See Figure 1.) Participating hospital data include date, time, result of BG measure, and download location (nursing unit). Patient-specific data, such as age, sex, race, diagnosis, Figure 1 . A proprietary software application is added to the existing RALS-Plus data management system in each hospital site. This application automatically extracts de-identified patient BG data, which are transferred via a secured internet connection to MAS, where reports are created and sent to the subscribers electronically. DMZ refers to "demilitarized zone", a computer term referring to a server outside the MAS company firewall that provides an extra layer of security. level of illness severity, or outcomes data, are not available. For this report, adult inpatient BG data from January 2006 through December 2009 was extracted. Out-of-range values of "LO" (<10 mg/dl) and "HI" (>600 mg/dl) were discarded as an exact measure was not available. The number of HI/LO values totaled <0.4% of the measurements. Additionally, all pediatric and outpatient data were excluded from this analysis as they reflect clinically different patient populations.
Hospital Selection
Participating hospitals were included through self-selection based on interest and willingness to complete a business agreement allowing de-identified data streaming to a central server prior to a data collection deadline. More than 1500 hospitals with RALS-Plus capability were invited to participate in the RALS-Annual Report. Confidentiality was guaranteed for the identity of participating hospitals and their data.
Statistical Analysis
Intensive care unit (ICU) and non-ICU download locations were analyzed separately and in combination. Glucose metrics included the mean and median BG results and the mean of all BG means and the mean of all BG medians for three separate categories per hospital (1) all inpatients combined, (2) ICU patient population only, and (3) non-ICU patients only. Rates of hyperglycemia and hypoglycemia were analyzed in the same manner. Due to variations in the definition of recommended inpatient glucose levels, 13 hyperglycemia was defined as BG >180 mg/dl; hypoglycemia was defined as BG <40 mg/dl (severe hypoglycemia) and <70 mg/dl (moderate hypoglycemia). Lowest mean BG and highest mean BG were determined by rank-ordering the hospitallevel mean of all measurements. All analyses used measurement-level data rather than by-patient-level data to calculate individual hospital metrics. A comparison of each hospital results with the aggregate of all hospitals and quartile ranking was also provided to the participant. Quartile 1 includes those hospitals with the lowest mean, while quartiles 2, 3, and 4 include hospitals with increasing hospital-level mean values. Aggregate results for the individual years 2006, 2007, 2008, and 2009 are presented in this report. All descriptive analyses were done using structured query language server data management system.
Results
A cumulative total of >175 million BG measurements collected from 576 hospitals were submitted from 2006 to 2009. A majority of the hospitals had ICUs (n = 533), were small (<200 beds, 47.4%), and located in urban areas (71.5%) in the southern U.S. region (47.7%). See Table 1 for participating hospital characteristics.
Mean BG results remained relatively constant for the entire hospital inpatient population and the separate ICU (25%) and non-ICU (75%) populations over the 4 study years ( Table 2) . Mean BG levels varied widely among the hospitals, with the range of lowest and highest ICU means being significantly wider (lower and higher) than the range of the non-ICU means (p < .001) and likely reflective of the intensity of glycemic control and the severity of illness in the ICU patients.
While even minor differences are statistically significant due to the sample size effect, the majority (62% of ICU, 84% of non-ICU) of hospital means can be found within the recommended acceptable glucose range (140-180 mg/dl) for hospital patients. a Assumptions: (1) BG data used is de-identified patient POC-BG data contained within the hospital RALS-Plus database, (2) ICU locations were identified according to the locations provided by the hospital, and (3) pediatric, neonatal, nursery, neonatal ICU, emergency room, and outpatient areas were excluded. b Value was determined by obtaining the mean result from each hospital and determining the lowest mean of all hospital means. c Value was determined by obtaining the mean result from each hospital and determining the highest mean of all hospital means. d Value was determined by adding all the results together and calculating the mean (average) result. e Value was determined by adding the mean result obtained from each of the hospitals and determining the median of all hospital means. f Value was determined by adding the mean result obtained from each of the hospitals and determining the mean of all hospital means. a The hospital's quartile is a number from 1 to 4. Quartiles provide a rough approximation of a hospital's performance relative to all participating hospitals. If hospital mean BG levels are arranged in order from lowest to highest, then one-quarter of hospitals with the lowest mean BG levels are assigned a quartile of 1, representing superior relative performance. Successive quarters are assigned quartiles of 2, 3, and 4. The quartile ranges are listed in Table 3a .
An example of an individual hospital summary is presented in Table 3 . As can be noted for this hospital, the number of ICU BG measurements in 2008 nearly doubled from the previous year, and the mean ICU BG decreased from 142 to 136 mg/dl (p < .001).
The quartile limits are also provided in this table for hospital reference in the range of BG means within this large sample.
Hypoglycemia and Hyperglycemia
As shown in Table 4 , mean hospital hypoglycemia rates were significantly lower for both severe and moderate hypoglycemia in 2009 in both ICU and non-ICU measures (p < .001). The reverse was seen with hyperglycemia, which increased during that same duration by significantly more (p < .0001).
Discussion
These data represent the largest inpatient database of BG results in the United States and allow a unique view of the state of inpatient glycemic control. The data are supported by other evaluations of hospital glycemic control in U.S. hospitals, where there was wide variation in hospital performance, hyperglycemia was common, and glucose control was suboptimal. 18, 22 A distinct advantage of this type of analysis is the complete automation of data collection without the need for hospital manual intervention and manipulation in order to monitor improvement in glycemic management. 3 mg/dl) (p < .001) . This may reflect the emerging evidence from the Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation (NICE-SUGAR) study.
8 NICE-SUGAR reported that glucose levels between 140 and 180 mg/dl in critically ill patients were tolerated and safer than lower targets that added risk of hypoglycemia. 8 However, overall there has been little clinically meaningful change, suggesting that hospitals are maintaining their glycemic control initiatives, with roughly 60% achieving the standard advised by the consensus report of the American Diabetes Association/ American Association of Clinical Endocrinologists (ADA/AACE). Table 4 ).
The study was limited by the self-selection of the participants in agreeing to allow data aggregation in return for their benchmarked data. The current participants represent approximately 38% of the total RALS-Plus user hospital population and are not necessarily representative of the U.S. hospital population. Interpretations of these findings are constrained by the absence of specific patient characteristics such as diagnosis and severity of illness, which would allow further subgroup analyses. Additionally, details of glycemic control program information, such as BG target ranges and management protocols, are not known for this report, although evidence in the measurement frequency and time between measures allows for patient-level analyses and examination of BG trends in individual hospital ICUs. These analyses were beyond the intent of this article to describe an automated reporting technology for hospitals. A second Web-based benchmarking report, Glucometrics TM , is available to hospitals without RALS connectivity and will offer reports in the future. Hospitals can use their institution's reports to examine their current glucose control as it relates to their quality of care and then adjust clinical practice as it pertains to patient glycemic management. Finally, the metrics presented here can assist in defining performance standards as a step toward improving glycemic managagment for individual hospitals and across health systems.
Conclusion
The RALS Report is designed to give caregivers and hospital administrators the ability to monitor BG trends in their hospital and track the impact of implementing glycemic control protocols for improving patient outcomes. The volume of test results automatically extracted for this mean BG analysis supersedes manual applications and provides a multihospital benchmark for best practices in glycemic control. Inpatient glycemic management remains an area of intense discussion in hospital patient care and is increasingly examined by national hospital quality agencies. 14 This national benchmarking initiative offers the potential for further in-depth examination and creates opportunity for extended research.
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